Trial Profile

"Aprepitant Trial" A phase II multi-centre trial of a seven day Aprepitant schedule for the prevention of chemotherapy induced nausea and vomiting in patients receiving five day cisplatin-based chemotherapy for germ cell tumours.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Jun 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aprepitant (Primary) ; Dexamethasone; Serotonin 3 receptor antagonists
Indications Chemotherapy-induced nausea and vomiting
Focus Therapeutic Use

19 Jan 2011 Status changed from recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
12 Jun 2009 Status changed from not yet recruiting to recruiting as reported by Australian New Zealand Clinical Trials Registry.
15 May 2009 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com